News

Aquestive Therapeutics (AQST) reported $12.05 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.3%. EPS of -$0.17 for the same period compares to $0.11 a year ago.

The reported revenue represents a surprise of -1.37% over the Zacks Consensus Estimate of $12.22 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -88.89%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Aquestive Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Manufacture and supply revenue: $10.52 million versus the four-analyst average estimate of $10.64 million. The reported number represents a year-over-year change of +7.7%.
• Revenues- License and royalty revenue: $1.13 million versus $1.20 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +23.2% change.
• Revenues- Co-development and research fees: $0.40 million compared to the $0.40 million average estimate based on three analysts. The reported number represents a change of -11% year over year.

View all Key Company Metrics for Aquestive Therapeutics here>>>

Shares of Aquestive Therapeutics have returned -14% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Where Will Stocks Go…

If Biden Wins? If Trump Wins?

The answers may surprise you.

Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!

Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…

1. Medical manufacturer has gained +11,000% in the last 15 years.

2. Rental company is absolutely crushing its sector.

3. Energy powerhouse plans to grow its already large dividend by 25%.

4. Aerospace and defense standout just landed a potentially $80 billion contract.

5. Giant Chipmaker is building huge plants in the U.S.

Hurry, Download Special Report FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.